Lupuzor Presentation

RNS Number : 2719Q

Immupharma PLC

05 November 2012

 



FOR IMMEDIATE RELEASE

5 NOVEMER 2012

RNS REACH

ImmuPharma to Present Lupuzor™ Phase IIb Abstract / Clinical Paper at

2012 Annual ACR Meeting, Washington, D.C.

Presentation Date: 14 November 2012

ImmuPharma PLC (LSE: IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to confirm that it will be presenting at the 2012 Annual American College of Rheumatology ("ACR") Meeting  which is being held between 11 - 14 of November. ImmuPharma will be presenting on Wednesday 14 November 2012. The ACR Annual Scientific Meeting is the premier scientific meeting devoted to rheumatic diseases.

ImmuPharma recently had confirmation that the ACR Abstract Selection Committee had accepted ImmuPharma's abstract paper on the Company's final clinical data for its Lupuzor^TM Phase IIb trial. Lupuzor^TM is ImmuPharma's potential blockbuster drug for Lupus, a chronic autoimmune disease. Lupuzor^TM has received Special Protocol Assessment and Fast Track Designation from the FDA for a Phase III trial. The title of the session is called "Systemic Lupus Erythematosus - Clinical Aspects and Treatment".

The presentation will be given by the authors of the abstract:  ImmuPharma's President and Chief Scientific Officer, Dr. Robert Zimmer, together with Pr. Daniel J. Wallace, Associate Director, Rheumatology Fellowship Program, Cedars-Sinai Medical Center, Los Angeles, and a leading practitioner within the field of Lupus, and Prof. Sylviane Muller, Research Director at CNRS, Strasbourg, France and the key inventor of Lupuzor^TM. (Full biographies can be found in 'Notes to Editors'.)

Analyst meeting: Friday 16 November at 10am

Venue: Buchanan, 107 Cheapside, London EC2V 6DN

Following the presentation at the ACR conference on 14th November, ImmuPharma will host an analyst meeting on Friday 16 November in London to provide full disclosure of the abstract paper and clinical analysis of the Lupuzor Phase IIb study. The presentation will be given by Dr Robert Zimmer and ImmuPharma's CEO, Dimitri Dimitriou. Please contact Lisa Baderoon, Head of Investor Relations, if you would like to attend ([e-mail]).

Ends

For further information please contact:

ImmuPharma plc	+ 44 (0) 20 7152 4080
Dimitri Dimitriou, Chief Executive Officer
Dr Robert Zimmer, President and Chief Scientific Officer
Richard Warr, Chairman
Lisa Baderoon, Head of Investor Relations	+ 44 (0) 7721 413496
Buchanan	+ 44 (0) 20 7466 5000
Mark Court
Panmure, Gordon & Co., NOMAD & Broker	[phone]
Andrew Burnett
Fred Walsh
Espirito Santo Investment Bank, Joint Broker	[phone]
Richard Crawley
Cenkos Securities plc, Joint Broker	[phone]
Stephen Keys, Camilla Hume
Andy Roberts

Notes to Editors

ImmuPharma

ImmuPharma is focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need.  ImmuPharma has five drug candidates in development, two platform technologies and approximately 70 patents.  The Company's most advanced drug candidate, Lupuzor^TM a potential blockbuster drug for Lupus, a chronic autoimmune disease has recently received the approval from the US FDA to enter phase III with a Special Protocol Assessment and "Fast Track" designation.  ImmuPharma was founded and is led by a commercially focused Board and management team with extensive experience. www.immupharma.com

Biographies

Dr Robert Zimmer, President and Chief Science Officer, ImmuPharma

Dr. Robert Zimmer was the founder and chief executive officer of both ImmuPharma Switzerland and ImmuPharma France. He is an expert in clinical pharmacology and life cycle management. He was instrumental in developing a substantial number of products for clients including Roche, GlaxoSmithKline, Abbott, Searle, Sanofi-Aventis and Lilly. He began his career in Roche's headquarters in Basle as coordinator of clinical pharmacology and international clinical leader. He subsequently joined Jago Pharma, the drug delivery company, and became a director and head of research and development at SkyePharma after it acquired JAGO. He obtained his MD at Strasbourg Medical School and his PHD at the University of Aix-Marseille.

Dr Sylviane Muller, Research Director at CNRS & Co-founder of ImmuPharma France

Sylviane Muller is Professor at the Institute for Advanced Study of the University of Strasbourg (USIAS), holder of the chair of immunology and therapeutic chemistry, Distinguished class Research Director  and head of the 'Immunologie et chimie thérapeutiques' unit of the "Centre National de la Recherche Scientifique" (CNRS), the largest fundamental research organization in  Europe. She obtained her PhD at the University of Strasbourg. For two years, she was a post-doctoral fellow in Freiburg (Germany) at the Max-Planck Institute for Immunobiology. Her field of expertise covers autoimmunity, immuno-peptides and synthetic vaccines. She has made 23 patented discoveries and is widely published (330 publications and reviews/chapters). She was also a founder of Neosystem, now Polypeptide-France, a leading peptide development and manufacturing company. She is the key inventor of ImmuPharma's Lupus lead drug candidate Lupuzor and has been working in this field for more than ten years.

Dr Daniel J Wallace, Associate Director, Rheumatology Fellowship Program, Cedars-Sinai Medical Center, Los Angeles

Dr Wallace received his undergraduate and medical education at the University of Southern California, graduating with an MD in 1974. His graduate medical training included an internship at Brown University in Providence, Rhode Island, medical residency at Cedars-Sinai Medical Center in Los Angeles and a fellowship in rheumatology at UCLA. He is Board Certified in both Internal Medicine and Rheumatology.

 While a fellow at UCLA, he conducted pioneering arthritis research that landed his picture in Time magazine and developed a close relationship with his mentor, Edmund Dubois. Dr Dubois had the largest lupus practice in the United States at the time and was the principal editor of the only lupus textbook. He is the author of 6 medical textbooks (including the last 4 editions of Dubois' Lupus Erythematosus, All About Fibromyalgia, The Lupus Book, All About Osteoarthritis, The New Sjogren's Syndrome Handbook, and Fibromyalgia & Other Central Pain Syndromes), 19 book chapters, and over 250 medical publications. The latter have appeared in the New England Journal of Medicine, Annals of Internal Medicine, the Lancet, Journal of Clinical Investigation, Journal of Immunology, and Journal of the American Medical Association. Wallace's academic efforts include having served as Chief of Rheumatology at Cedars-Sinai Medical Center, Century City Hospital, and the City of Hope Medical Center in Duarte, CA. He is currently a Clinical Professor of Medicine at the David Geffen School of Medicine at UCLA. His clinical practice is based at Cedars-Sinai, where he is involved in the care of 2,000 lupus patients, the largest practice of its kind in the United States. The Wallace Rheumatic Disease Research Center currently runs over 30 clinical trials for patients with rheumatoid arthritis, lupus, ankylosing spondylitis, psoriatic arthritis and fibromyalgia. The center has been the recipient of 3 National Institute of Health grants. 20% of his time is spent in teaching and research, providing free medical care.

About The American College of Rheumatology "ACR"

The American College of Rheumatology's mission is advancing rheumatology. The organization is for physicians, health professionals, and scientists that meets the mission through programs of education, research, advocacy and practice support.

The ACR provides professional education for its members through several venues. The Annual Scientific Meeting is the premier scientific meeting devoted to the rheumatic diseases. This meeting draws thousands of rheumatologists and arthritis health professionals from around the world. A winter rheumatology symposium, spring clinical meetings, and other topical conferences round out the ACR's educational offerings.

The ACR publishes Arthritis & Rheumatism, the premier scientific journal for research in the rheumatic diseases. Arthritis Care & Research is published by the Association of Rheumatology Health Professionals, a division of the ACR. This journal focuses on the health services and clinical aspects of rheumatology.

The Association of Rheumatology Health Professionals, a division of the American College of Rheumatology, is a professional membership society composed of non-physician health care professionals specializing in rheumatology, such as advanced practice nurses, nurses, occupational therapists, physical therapists, psychologists, social workers, epidemiologists, physician assistants, educators, clinicians, researchers, research coordinators and office staff.

The ACR Annual Meeting - The Premier Meeting in Rheumatology

The ACR Annual Meeting is the must-attend event for anyone involved in research or delivery of rheumatologic care or services. Innovative sessions, ground breaking scientific abstracts, education developed based on practice gaps, the return of popular session formats, as well as hands-on skill training sessions are just some of the highlights. 

 

END

 

 

NRALLFSDLRLFIIF